ALBUQUERQUE, N.M., May 5, 2026
Eden Radioisotopes, LLC has filed a Construction Permit Application with the U.S. Nuclear Regulatory Commission (NRC) to establish a large-scale medical isotope production facility near Eunice, New Mexico, marking a pivotal step toward securing a domestic supply of critical radiopharmaceutical materials. The proposed facility is designed to produce essential isotopes such as Molybdenum-99 (Mo-99) and Lutetium-177 (Lu-177), which are widely used in diagnostic imaging and targeted cancer therapies, addressing a long-standing gap in the U.S. healthcare infrastructure.
Domestic Isotope Production to Strengthen Healthcare Supply Chain
The Eden facility aims to deliver up to 50% of global demand for Mo-99, a key isotope used in more than 40,000 diagnostic imaging procedures daily in the United States, including cardiac and cancer scans. Currently, the U.S. relies on 100% imported supply from aging foreign nuclear reactors, creating a fragile supply chain vulnerable to disruptions.
Medical isotopes such as Mo-99 are highly time-sensitive, with short half-lives that prevent long-term storage, making reliable and continuous production essential. Any interruption in global supply can result in immediate cancellation of critical diagnostic procedures, directly impacting patient care. By establishing a domestic production hub, Eden aims to ensure supply stability, reduce dependency on foreign sources, and enhance national healthcare resilience.
In addition to Mo-99, the facility will produce over 3.5 million annual doses of Lu-177, an advanced radiotherapeutic isotope used in targeted cancer treatments, further expanding the availability of precision oncology therapies in the United States.
Advertisement
Advanced Nuclear Technology Enables Scalable Production
Eden’s isotope production complex is based on an “all-target” reactor design licensed from Sandia National Laboratories, optimized for high-yield isotope generation without producing spent nuclear fuel. This innovative approach represents a significant advancement in nuclear medicine manufacturing, combining efficiency, safety, and sustainability.
The facility will also include a co-located processing unit, enabling rapid extraction and distribution of isotopes, which is critical given their short decay times. This integrated design enhances operational efficiency and ensures timely delivery to healthcare providers, supporting both diagnostic and therapeutic applications.
Strategically located in southeastern New Mexico, the facility benefits from infrastructure, regulatory alignment, and logistical advantages, positioning it as a commercially viable and scalable solution for long-term isotope production. The company has emphasized that its design aligns with modern regulatory expectations and safety standards, strengthening its case for expedited approval.
Regulatory Momentum and National Policy Support
The permit application comes amid growing federal efforts to support domestic medical isotope production, including the American Medical Isotope Production Act of 2012, which encourages the development of reliable U.S.-based supply chains. Despite these initiatives, the country has yet to achieve sufficient domestic production capacity, highlighting the importance of Eden’s project.
Recent regulatory reforms under the ADVANCE Act of 2024 and Executive Order 14300 aim to streamline licensing processes for advanced nuclear technologies, including non-power reactors used for medical applications. Eden has indicated confidence in a 12-month NRC review timeline, citing early engagement with regulators, a robust application process, and comprehensive environmental assessments.
This regulatory momentum reflects a broader shift toward leveraging nuclear technology for healthcare innovation, where isotopes play a critical role in early diagnosis, targeted treatment, and improved patient outcomes.
Implications for Pharma and Radiopharmaceutical Innovation
The development of a domestic isotope production facility has far-reaching implications for the pharmaceutical and radiopharmaceutical industries, particularly in the areas of oncology, cardiology, and diagnostic imaging. Reliable access to isotopes is essential for the production of radiopharmaceutical drugs, which combine radioactive materials with targeting molecules to deliver precision therapies and imaging capabilities.
Eden’s initiative supports the growing demand for personalized medicine, where targeted radiotherapies like Lu-177 are increasingly used to treat cancers with high specificity and reduced side effects. By ensuring a stable supply of isotopes, the facility will enable continued innovation in drug development, clinical research, and patient care.
Furthermore, the project highlights the intersection of pharmaceutical manufacturing, nuclear technology, and regulatory science, demonstrating how integrated approaches can address complex healthcare challenges and improve system-wide efficiency.
Source: Eden Radioisotopes press release
